多西他赛联合奈达铂同步放化疗治疗中晚期宫颈癌的疗效观察与生存分析  

Efficacy Observation and Survival analysis of Docetaxel Combined with Nedaplatin concurrent Chemoradiotherapy in Advanced cervical Cancer

作　　者：郭峰 姜赛君 马淑云[1] 韩易宇 陈采枝 邹文[1] GUO Feng;JIANG Sai-jun;MA Shu-yun;HAN Yi-yu;CHEN Cai-zhi;ZHOU Wen(Cancer Center,The Second Xiangya Hospital of Central South University,Changsha Hunan,410011,China)

机构地区：[1]中南大学湘雅二医院肿瘤中心,湖南长沙410011

出　　处：《医学食疗与健康》2020年第23期67-69,共3页Medical Diet and Health

摘　　要：目的:观察多西他赛联合奈达铂同步放化疗治疗局部晚期宫颈癌的疗效、不良反应及3年生存率。方法:105例首治颈癌患者,I给与多西他赛75mg/m2+奈达铂80mg/m2,静脉滴注,21d为一.个周期,所有患者完成4.~6个周期化疗;同步行宫颈放疗(体外照射加192r.腔内照射),观察疗效及不良反应。结果:105例患者有效率为886%,3年总生存率为838%。不良反应方面3~4级白细胞降低的发生率为57%,未出现3~4级血小板降低。未出现3~4级放射性肠炎及膀胱炎。结论:多西他赛联合奈达铂同步放化疗治疗中晚期宫颈癌的疗效确切,耐受性好,为一安全有效的化疗方案。Objective:To observe the efficacy,adverse reactions and 3-year survival rate of docetaxel combined with nedaplatin and radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer.Methods:A total of 105 first treated patients with stage IIB-IVA cervical cancer were given docetaxel 75mg/m2 plus nedaplatin 80mg/m2,with intravenous infusion.Twenty-one days for one cycle,all patients completed 4-6 cycles of chemotherapy.Simultaneously,cervical radiotherapy(extracorporeal irradiation plus 192 Ir intracavitary irradiation)was performed to observe the efficacy and adverse reactions.Results:In 105 patients,the effective rate was 88.6%,the 3-year total survival rate was 83.8%,and the incidence of grade 3-4 leukopenia in adverse reactions was 5.7%.No grade 3-4 low platelet count and grade 3-4 radiation enterocolitis and cystitis occurred.Conclusion:Docetaxel combined with nedaplatin and radiotherapy and chemotherapy,as a safe and effective chemotherapy regimen,has accurate efficacy and well tolerance in the treatment of middle and advanced cervical cancer.

关 键 词：宫颈癌 多西他赛 奈达铂 同步放化疗 

分 类 号：R737.33[医药卫生—肿瘤]